Ho et al., 1984 - Google Patents
Paradoxical effects of interferon on reactivation of oral infection with herpes simplex virus after microvascular decompression for trigeminal neuralgiaHo et al., 1984
- Document ID
- 1771877049584541174
- Author
- Ho M
- Pazin G
- Armstrong J
- Haverkos H
- Dummer J
- Jannetta P
- Publication year
- Publication venue
- Journal of Infectious Diseases
External Links
Snippet
Fifty-five patients undergoing microvascular decompression for trigeminal neuralgia were divided into three groups in a two-stage placebo-controlled study. All groups received two injections a day for five days beginning the day before surgery. Twenty-one patients …
- 206010044652 Trigeminal neuralgia 0 title abstract description 7
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69219782T2 (en) | USE OF A THYMOSIN IN TREATING HEPATITIS C | |
| Bork et al. | Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency | |
| Milligan et al. | Interferon-γ enhances resolution of herpes simplex virus type 2 infection of the murine genital tract | |
| Doorn et al. | High‐dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double‐blind, placebo‐controlled, crossover study | |
| Thorley-Lawson | The transformation of adult but not newborn human lymphocytes by Epstein Barr virus and phytohemagglutinin is inhibited by interferon: the early suppression by T cells of Epstein Barr infection is mediated by interferon. | |
| DE68911019T2 (en) | Combined hepatitis A and B vaccine with adjuvant. | |
| DE69330032T2 (en) | THERAPEUTIC COMBINATION PREPARATION CONTAINING INTERFERON | |
| DE69333321T3 (en) | Use of a consensus interferon to reduce side effects in the interferon treatment of viral hepatitis. | |
| Porter et al. | Aphthous stomatitis—an overview of aetiopathogenesis and management | |
| Sullivan et al. | Inhibition of lymphocyte stimulation by measles virus | |
| Bonetti et al. | Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2α | |
| EP0109234B1 (en) | Compositions comprising interferon and their therapeutic use | |
| US5624938A (en) | Use of chloroquine to treat multiple sclerosis | |
| Ho et al. | Paradoxical effects of interferon on reactivation of oral infection with herpes simplex virus after microvascular decompression for trigeminal neuralgia | |
| CA2372099C (en) | Antiviral agent in the form of nose drops | |
| EP0101200A2 (en) | Transfer factor for use in treating viral infections | |
| US4806347A (en) | Interferon combinations | |
| US20020025316A1 (en) | Pharmaceutical composition containing inhibitors of interferon-gamma | |
| Pinto et al. | Comparative study of various immunomodulators for macrophage and natural killer cell activation and antiviral efficacy against exotic RNA viruses | |
| WO1994001125A1 (en) | Composition and method of treating hepatitis b | |
| CA1296252C (en) | Method and composition for prophylaxis and treatment of viral infections | |
| Van den Broek et al. | Limited value of acyclovir in the treatment of uncomplicated herpes zoster: a placebo-controlled study | |
| Wolinsky et al. | Progressive rubella panencephalitis: immunovirological studies and results of isoprinosine therapy | |
| Klein et al. | Effect of acyclovir on latent herpes simplex virus infections in trigeminal ganglia of mice | |
| IE841373L (en) | Anti-tumour gamma-interferon-lymphotoxin composition |